"目录号: HY-14803
GPCR/G ProteinNeuronal Signaling-
Tasimelteon是褪黑素MT1和MT2受体激动剂。
相关产品
生物活性
Description
Tasimelteon is a melatonin MT1 and MT2 receptor agonist.Target: melatonin receptorTasimelteon is a novel circadian regulator, is the first product for the treatment of Non-24-hour Sleep-Wake Disorder (Non-24) approved by either the FDA or the European Medicines Agency (EMA). Tasimelteon is a potent and specific melatonin (MT1 and MT2) receptor agonist with 2 - 4 times greater affinity for the MT2 receptor.
Clinical Trial
Vanda Pharmaceuticals
Non-24-Hour-Sleep-Wake Disorder
May 2014
Phase 4
Vanda Pharmaceuticals
Hepatic Impairment
January 2011
Phase 1
Vanda Pharmaceuticals
Healthy Volunteers
November 2011
Phase 1
Vanda Pharmaceuticals
Non-24-Hour Sleep-Wake Disorder
October 2011
Phase 3
Vanda Pharmaceuticals
Non 24 Hour Sleep Wake Disorder
September 2010
Phase 3
Vanda Pharmaceuticals
Circadian Rhythm Sleep Disorders-Non-24 Hour Sleep-Wake Disorder-Autism Spectrum Disorder-Smith-Magenis Syndrome
September 2016
Phase 1
Vanda Pharmaceuticals
Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol
April 2012
Phase 1
Vanda Pharmaceuticals
Healthy Volunteers
February 2012
Phase 1
Vanda Pharmaceuticals
Renal Impairment
February 2012
Phase 1
Vanda Pharmaceuticals
Non-24-Hour Sleep-Wake Disorder
August 2010
Phase 3
Vanda Pharmaceuticals
Healthy
June 2012
Phase 1
Vanda Pharmaceuticals
Major Depressive Disorder
September 2011
Phase 2-Phase 3
Vanda Pharmaceuticals
Smith-Magenis Syndrome-Circadian
September 2015
Phase 2-Phase 3
Vanda Pharmaceuticals
Non-24-Hour Sleep-Wake Disorder
September 2011
Phase 3
Vanda Pharmaceuticals
Healthy Volunteers
August 2011
Phase 1
Vanda Pharmaceuticals
Primary Insomnia
November 2007
Phase 3
Vanda Pharmaceuticals
Circadian Rhythm Sleep Disorders
July 2004
Phase 2
Vanda Pharmaceuticals
Insomnia
February 2006
Phase 3
View MoreCollapse
References
